News & Regulatory

Peptide & Telehealth News

Source-cited coverage of the FDA rulings, regulatory shifts and research that change what you can access online. Editorially independent, every claim referenced.

RegulatorySep 12, 2026·7 min read

FDA Blocks Imports and Prompts Recall of Sildenafil and Tadalafil Ingredients From an Indian Plant That Supplied U.S. Compounding Pharmacies

The FDA placed Shoolin Pharma Chem on import alert on August 11, 2026 and the firm recalled its U.S. drug ingredients after an April inspection found insanitary conditions at its Gujarat, India plant. The APIs include sildenafil and tadalafil used by compounding pharmacies, the same active ingredients behind many telehealth erectile dysfunction programs.

BusinessSep 11, 2026·7 min read

Department of Veterans Affairs Issues Amwell a Letter of Intent to Power Its Virtual Health Platform, Pending a Definitive Contract

On September 8, 2026, the VA issued Amwell a non-binding letter of intent to deploy its virtual health platform across the VA enterprise, potentially reaching more than 9 million Veteran beneficiaries. Any formal deal still depends on a definitive contract and federal procurement requirements.

RegulatorySep 10, 2026·8 min read

DEA's Telemedicine Special Registration Final Rule Reaches White House Review

The DEA sent its final telemedicine special registration rule (RIN 1117-AB40) to the White House OIRA on August 25, 2026, the last major step before a rule can publish. If finalized, it would create a permanent pathway for prescribing controlled substances by telehealth. Current flexibilities expire December 31, 2026.

BusinessSep 9, 2026·8 min read

Quel Health Launches as a National Telehealth Company Prescribing GLP-1 Drugs Off-Label for Addiction

Quel Health, Inc. launched September 8, 2026, describing itself as the first national telehealth company built around GLP-1 receptor agonists for addiction. The medications are prescribed off-label: the FDA has not approved GLP-1 drugs for any substance use disorder, and the underlying evidence is early and mostly focused on alcohol.

LegalSep 5, 2026·8 min read

Fifth Circuit Sets September 9 Oral Argument in Louisiana's Challenge to Telehealth Prescribing of Mifepristone

The Fifth Circuit is scheduled to hear oral argument September 9, 2026, in State of Louisiana et al. v. FDA (No. 26-30203), a challenge to the FDA's 2023 decision to drop the in-person dispensing rule that had blocked telehealth prescribing and mail delivery of mifepristone. Access is unchanged for now under a Supreme Court stay while the appeal proceeds.

RegulatorySep 4, 2026·8 min read

CMS Confirms Its Pandemic-Era Telehealth Enrollment Flexibility Is Now Permanent, Letting Home-Based Clinicians Enroll and Bill From a Physical Practice Location

CMS guidance current as of mid-2026, and highlighted in the agency's August 20, 2026 Medicare Learning Network newsletter, confirms that clinicians who furnish Medicare telehealth from home but keep a physical practice location no longer have to report their home address to enroll. The flexibility does not extend to teleradiology, and state licensure rules still apply.

RegulatorySep 2, 2026·8 min read

FDA Broadens Its Consumer Safety Alert to Cover All Unapproved GLP-1 Weight-Loss Drugs, With New Telehealth Red Flags

The FDA's consumer safety communication, current as of September 1, 2026, warns that unapproved and compounded GLP-1 drugs skip FDA review and lists telehealth warning signs to avoid. The agency says it has received hundreds of adverse event reports tied to compounded semaglutide and tirzepatide.

LegalSep 1, 2026·8 min read

Third Circuit Upholds New Jersey's Requirement That Out-of-State Doctors Hold a New Jersey License Before Treating Patients by Telemedicine

On August 31, 2026, the U.S. Court of Appeals for the Third Circuit affirmed the dismissal of a constitutional challenge to New Jersey's rule that any physician practicing telemedicine with a patient in the state must first hold a New Jersey medical license. The precedential decision held the requirement is a content-based speech regulation that survives because medical licensing fits a long tradition of such rules.

RegulatoryAug 31, 2026·6 min read

FCC Publishes Rural Health Care Program Proposal in the Federal Register, Opening a Public Comment Period

The FCC's Third Further Notice of Proposed Rulemaking on the Rural Health Care Program (WC Docket No. 17-310, FCC 26-54), adopted August 6, 2026, was published in the Federal Register on August 31, 2026, opening a public comment period. Comments are due September 30, 2026 and reply comments October 30, 2026. It is a proposal seeking comment, not a final rule.

LegalAug 30, 2026·9 min read

Fifth Circuit Affirms FDA's Decisions to End the GLP-1 Drug Shortages, Upholding Limits on Compounded Semaglutide and Tirzepatide

On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two judgments for the FDA, upholding the agency's removal of Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) from its drug shortage list. Because federal law only relaxes the ban on compounding copies of an approved drug while it is in shortage, the rulings leave in place the legal limits on mass compounding of these GLP-1 medicines, which many patients obtain through telehealth. Here is what the decisions say and what they mean.

AccessAug 28, 2026·7 min read

Georgia Rural Hospitals to Receive $93.3 Million in Federal Rural Health Transformation Funds for Telehealth and Surgical Robotics

CMS announced on August 27, 2026 that Georgia will receive $93.3 million through the federal Rural Health Transformation Program to expand telehealth, add surgical robotics, and modernize care at 87 rural hospitals. The award completes Georgia's full $218 million first year allocation under the $50 billion national program.

RegulatoryAug 25, 2026·6 min read

Houston Pharmacy Recalls Compounded Glutathione Across 14 States, the Second Texas Endotoxin Recall in Two Weeks

Optimal Balance Pharmacy of Houston, Texas is voluntarily recalling one lot of Compounded Glutathione 200 mg/mL multi-dose vials to the patient level after its own testing found elevated bacterial endotoxin. The product reached patients in 14 states, and the pharmacy says it has received adverse-event reports. It is the second Texas compounding pharmacy in about two weeks to recall injectable glutathione for the same reason.

AccessAug 22, 2026·7 min read

Dartmouth Health Plans to End Its Tele-ICU and Tele-ED Programs for 13 Rural Hospitals in New Hampshire and Vermont, Citing Unsustainable Costs

Dartmouth Health plans to end its Tele-ICU and Tele-ED programs, which remotely support the intensive care units and emergency departments of 13 rural hospitals in New Hampshire and Vermont, citing costs a spokesperson called unsustainable without external funding after a reported $63.5 million operating deficit. No firm end date is set, and the system says it will help affected hospitals line up alternatives first. Here is what is closing, who is affected, and what it signals for rural telehealth.

LegalAug 18, 2026·9 min read

Bupe.me and Church Ekklasia Sozo: Inside the Telehealth Opioid Nonprofit at the Center of a Federal Buprenorphine Prescribing Case

Church Ekklasia Sozo, which operated online as Bupe.me, was a North Carolina nonprofit that prescribed the addiction medication buprenorphine to thousands of patients through telemedicine. Federal investigators say prescriptions were issued using clinicians' DEA registrations without the clinicians evaluating patients. Here is what is known about the company, its founder Doug Smith, the one conviction so far, and what remains under investigation.

LegalAug 18, 2026·6 min read

North Carolina Physician Sentenced After a Telemedicine Company Used His DEA Registration for More Than 25,000 Buprenorphine Prescriptions

A federal court sentenced Waxhaw physician Dr. Henry Ronald Emery Jr. to six months in prison and one year of supervised release after prosecutors said he let a telemedicine opioid treatment company use his DEA registration to issue more than 25,000 buprenorphine prescriptions to patients he never interacted with. Here is what the case shows about controlled substance prescribing by telehealth, and how it differs from legitimate online treatment for opioid use disorder.

LegalAug 15, 2026·8 min read

Ninth Circuit Revives a Justice Department Subpoena to Telehealth Provider QueerDoc and Sends the Overbreadth Question Back to the Trial Court

On August 14, 2026, a divided Ninth Circuit panel reversed a Seattle judge who had quashed a Justice Department administrative subpoena to QueerDoc, a telehealth clinic, and sent the case back to weigh whether the demand is overbroad. QueerDoc has not been charged with any violation and the investigation is pending. Here is what the ruling decided, the subpoena authority at issue, and what it signals for telehealth providers.

RegulatoryAug 14, 2026·7 min read

Apollo Care Recalls More Than 162,000 Vials of Compounded Semaglutide Nationwide After Particulate Matter Found

Apollo Care, LLC, an FDA registered 503B outsourcing pharmacy in Columbia, Missouri, is voluntarily recalling more than 162,000 multi-dose vials of compounded semaglutide nationwide after particulate matter identified as nylon/polyamide and silk/proteinaceous material was found in the vials. The firm initiated the recall on July 29, 2026, and the FDA has classified it as a Class II recall.

AccessAug 11, 2026·8 min read

Medicare's GLP-1 Bridge: How the $50 Weight-Loss Drug Demonstration Works

The Medicare GLP-1 Bridge is a CMS demonstration that, from July 1, 2026 through December 31, 2027, lets eligible Medicare Part D enrollees get certain weight-loss GLP-1 drugs for a $50 monthly copay. Here is who qualifies, which drugs are covered, and how the program works outside the normal Part D benefit.

LegalAug 8, 2026·7 min read

Federal Court Dismisses Compounder's GLP-1 Antitrust Suit Against Eli Lilly and Novo Nordisk Over Telehealth Deals

A federal judge in Texas dismissed Strive Specialties' antitrust lawsuit against Eli Lilly and Novo Nordisk, which alleged the drugmakers used exclusive telehealth partnerships to lock compounded GLP-1 pharmacies out of the market. The court found compounded and branded GLP-1 drugs do not compete in the same market. Here is what the ruling says and what it means for telehealth GLP-1 access.

RegulatoryAug 7, 2026·7 min read

CMS Proposes to Expand the Medicare Telehealth List and Add New Telehealth Modifiers in the CY2027 Fee Schedule

In the proposed CY2027 Medicare Physician Fee Schedule (CMS-1848-P, released July 14, 2026), CMS proposes adding five services to the Medicare Telehealth Services List, creating two informational telehealth modifiers (BB and BC) to flag third-party platform and incident-to arrangements, raising the originating site facility fee to $32.65, and implementing the Consolidated Appropriations Act, 2026 telehealth flexibilities through the end of 2027. Nothing is final. Public comments are due September 14, 2026.

AccessAug 7, 2026·7 min read

New Jersey Revises the Rules for Prescribing Schedule II Controlled Substances by Telemedicine

A New Jersey law enacted in July 2026, P.L. 2026, c. 40, amends N.J.S.A. 45:1-62 and keeps an in-person examination as the default for prescribing a Schedule II controlled dangerous substance by telemedicine, both at the start of care and every three months, unless a statutory exception applies. The law adds a telehealth pathway for adult stimulant prescriptions and full exceptions for patients in cancer, hospice, palliative, or long-term care, patients under the Medical Aid in Dying Act, and medications used to treat a substance use disorder.

RegulatoryAug 6, 2026·6 min read

Texas Pharmacy Recalls Compounded Glutathione Injection Nationwide After Elevated Endotoxin Levels

Victory Medical Center Pharmacy of Austin, Texas is voluntarily recalling three lots of Compounded Glutathione 200 mg/mL multi-dose vials to the patient level after its own testing found elevated bacterial endotoxin levels. The pharmacy says it has received reports of adverse events including fever, chills and tachycardia.

AccessAug 4, 2026·6 min read

CMS Will Require Rural Health Clinics and FQHCs to Bill Individual Telehealth Codes Instead of G2025 Starting October 1, 2026

Starting October 1, 2026, Medicare will require rural health clinics (RHCs) and federally qualified health centers (FQHCs) to bill the individual CPT or HCPCS code for each distant site telehealth service instead of the bundled code G2025, and to add modifier 93 (audio only) or 95 (audio and video). CMS set the requirement in Change Request 14468 (Transmittal R13776OTN), effective October 1, 2026 with an implementation date of October 5, 2026. It is a coding and reporting change, not a change to coverage, and payment stays tied to national average Physician Fee Schedule telehealth rates.

RegulatoryAug 3, 2026·6 min read

FCC Is Scheduled to Take Up a Rural Health Care Program Overhaul Aimed at Cutting Telehealth Red Tape

The FCC is scheduled to consider Promoting Telehealth in Rural America (WC Docket No. 17-310) at its August 6, 2026 open meeting, a Third Further Notice of Proposed Rulemaking and Order that would seek comment on cutting administrative burdens in the Rural Health Care Program and would let rural providers reuse previously approved rural rates for funding year 2027. It is a proposal that only seeks comment, not a final rule.

LegalAug 2, 2026·8 min read

Three Sentenced in $2 Billion Telemedicine Fraud as Alleged Ringleader Remains at Large in Russia

In May 2026 a federal court in Brooklyn sentenced three members of an international criminal organization to lengthy prison terms for a roughly $2 billion telemedicine health care fraud that billed private insurers using sham online visits. The man prosecutors identify as the leader, Brian Sutton, has not been tried and is reported to be living freely in Russia. Here is what the Justice Department proved, what remains an allegation, and what the case shows about telehealth fraud.

LegalJul 30, 2026·7 min read

FTC and Two States Sue Hims & Hers Over Alleged Health Data Sharing and Billing Practices

The FTC, joined by Utah and California, sued telehealth company Hims & Hers on July 29, 2026, alleging it shared sensitive health data with Meta and Snap and used deceptive billing and cancellation practices. These are allegations, not findings, and the case will be decided by a court.

RegulatoryJul 29, 2026·8 min read

FDA Publishes Revised Draft Guidances Aimed at Generic Versions of Peptide Drugs, Including GLP-1 Medicines

On July 28, 2026, the FDA released 17 revised draft product-specific guidances that spell out how companies can develop generic versions of peptide drugs, including GLP-1 medicines such as semaglutide and tirzepatide. The guidances are proposals open for public comment through September 28, 2026, not approvals of any generic product.

LegalJul 27, 2026·7 min read

Telehealth Company Drops Compounded Semaglutide Weight Loss Claims After Novo Nordisk Ad Challenge

On July 24, 2026, BBB National Programs' National Advertising Division said Willow Health Services, a telehealth company, permanently discontinued advertising claims for its compounded semaglutide products after a challenge by Novo Nordisk. Here is what the self-regulatory case decided, what claims were at issue, and what it signals for the compounded GLP-1 market.

LegalJul 26, 2026·6 min read

Austin Men's Health Clinic Chain Agrees to Up to $600,000 in Controlled Substances Act Settlement

Total MD Physicians Group, doing business as Total Men's Primary Care, and Dr. Mason Jones agreed to a consent judgment of up to $600,000 to resolve alleged Controlled Substances Act violations, including recordkeeping failures and electronically signing Schedule II prescriptions without a doctor-patient relationship. The claims are allegations only, with no determination of liability.

RegulatoryJul 25, 2026·8 min read

FDA Advisory Panel Recommends Six of Seven Peptides for Compounding, Overriding FDA Staff

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides, including BPC-157 and TB-500, for the 503A compounding list, going against FDA scientists who urged rejection. Only emideltide (DSIP) was turned down. The recommendation is advisory and would still require a formal FDA rulemaking. Here are the tallies, the conflict-of-interest concerns, and what happens next.

RegulatoryJul 24, 2026·7 min read

FDA Picks Dexcom as First Participant in Its TEMPO Digital Health Devices Pilot

On July 22, 2026, the FDA named Dexcom as the first participant in its TEMPO for Digital Health Devices Pilot, a voluntary program run with the CMS Innovation Center that has device makers collect and report real-world data tied to the CMS ACCESS Model for chronic care. Here is what the pilot covers, how it connects to Medicare coverage, and what is not yet settled.

RegulatoryJul 22, 2026·7 min read

CMS Proposes Ending Medicare Pay for Outsourced Remote Patient Monitoring

CMS's proposed CY2027 Physician Fee Schedule rule, published July 16, 2026, would end Medicare payment for remote physiologic and remote therapeutic monitoring performed by outsourced, third party vendors, requiring that service instead come from a practice's own employed clinical staff. Comments are due September 14, 2026, and nothing has been finalized.

LegalJul 22, 2026·6 min read

Idaho Physician Sentenced in Telemedicine Medicare Fraud Scheme

A federal judge sentenced Coeur d'Alene physician David Antonio Becerril to 40 months in prison and more than $1.25 million in restitution for signing Medicare orders through a telemedicine company for patients he never examined. Here is what the case shows about telehealth fraud, and how it differs from legitimate telehealth.

RegulatoryJul 22, 2026·9 min read

FDA Peptide Vote: What the July 23-24 PCAC Meeting Means for Access

The FDA's Pharmacy Compounding Advisory Committee reviews BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon on July 23-24, 2026. FDA's briefing documents recommend against all seven. Here is what the vote decides and what it means for patient access.

ExplainerJul 22, 2026·6 min read

The 503A Bulks List, Explained: How the FDA Decides Which Peptides Pharmacies Can Compound

The 503A Bulks List controls which non-approved substances compounding pharmacies can legally prepare. Here is how it works, how 503A differs from 503B, and why it decides peptide access in the US.